<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669081</url>
  </required_header>
  <id_info>
    <org_study_id>00094756</org_study_id>
    <nct_id>NCT03669081</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effects of Toradol and Lyrica for Pain Control After Donor Nephrectomy</brief_title>
  <official_title>A Prospective, Double-blind, Randomized Pilot Study Evaluating the Effects of Toradol and Lyrica Verses Placebo for Pain Control After Donor Nephrectomy (TORPEDO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will assess how the use of toradol and pregabalin affects return to bowel
      function and see if there is a difference in length of hospital stay. Narcotic use can affect
      bowel function so the investigators hypothesize that use of Toradol will decrease delayed
      bowel function and aid in a patients discharge and reduction of hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative pain management is a significant challenge following surgery. Many pathways
      contribute to perioperative pain, including nociceptive, inflammatory, and neuropathic
      sources. Although opioids have long been a mainstay for perioperative analgesia, other
      non-opioid therapies have been increasingly used as part of a multimodal analgesic regimen to
      provide improved pain control while minimizing opioid-related side effects

      TORADOL (ketorolac tromethamine), is a nonsteroidal anti-inflammatory drug (NSAID), is
      indicated for the short-term (up to 5 days in adults), management of moderately severe acute
      pain that requires analgesia at the opioid level.

      Anecdotal evidence has shown that the use of Toradol (Ketorolac) is safe in renal surgery
      patients. The study team aims to further evaluate this in a pilot study specifically in the
      population of patient who have donated their kidney in live kidney transplants. The study
      team will assess how the use of toradol affects return to bowel function and see if there is
      a difference in length of hospital stay. Narcotic use can affect bowel function so the
      investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in
      a patients discharge and reduction of hospital stay. The study team will assess differences
      in visual analog pain scores and total narcotic consumption, whereas secondary endpoints of
      urine output, serum creatinine and hemoglobin levels to assess for efficacy and safety.

      Pregabalin is prescribed for neuropathic pain. In many studies, preoperative administration
      of pregabalin reduced postoperative morphine consumption and early postoperative pain.

      There will be two arms of the study including:

      Arm 1 (pure placebo group): Placebo oral preop then Saline placebo IV x 1 in the OR, then
      saline placebo IV every 6 hours for 7 doses.

      Arm 2: Pregabalin 75mg oral preop, then Ketorolac 30 mg IV x 1 in the OR, then ketorolac 15
      mg IV every 6 hours for 7 doses.

      Toradol and Lyrica will be used consistent with its FDA approval in terms of dosing, route of
      administration, etc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2016</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Narcotic Use</measure>
    <time_frame>82.25 hours</time_frame>
    <description>Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>82.25 hours</time_frame>
    <description>Primary outcomes include length of hospital stay (LOS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine Levels at One Year Post-operatively</measure>
    <time_frame>1 year</time_frame>
    <description>Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Risk</measure>
    <time_frame>24 hours</time_frame>
    <description>Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Urinary Retention</measure>
    <time_frame>82.25 hours</time_frame>
    <description>Patients were evaluated post-operatively during hospital stay for instances of urinary retention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Primary outcomes include 30 day mortality post-operatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Toradol and Lyrica</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.</description>
    <arm_group_label>Toradol and Lyrica</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
    <arm_group_label>Toradol and Lyrica</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo oral capsule was administered orally 30 minutes prior to operation.</description>
    <arm_group_label>Placebo and Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
    <arm_group_label>Placebo and Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients anticipating donating a kidney in a live kidney donor transplant.

        Exclusion Criteria:

          -  Patients not receiving a donor nephrectomy

          -  Pregnant, lactating, or nursing mothers

          -  Medical allergies or history that would otherwise be contraindicated for of a
             non-steroidal anti-inflammatory drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <results_first_submitted>April 15, 2019</results_first_submitted>
  <results_first_submitted_qc>July 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2019</results_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Jeffrey Campsen</investigator_full_name>
    <investigator_title>Associate Professor of Transplant Surgery</investigator_title>
  </responsible_party>
  <keyword>live kidney donor</keyword>
  <keyword>donor nephrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03669081/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03669081/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Toradol and Lyrica</title>
          <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
        </group>
        <group group_id="P2">
          <title>Placebo and Standard of Care</title>
          <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Data could not be validated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Toradol and Lyrica</title>
          <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Standard of Care</title>
          <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="11"/>
                    <measurement group_id="B2" value="45.1" spread="12.2"/>
                    <measurement group_id="B3" value="44.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Narcotic Use</title>
        <description>Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.</description>
        <time_frame>82.25 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Narcotic Use</title>
          <description>Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="13" upper_limit="42.3"/>
                    <measurement group_id="O2" value="45" lower_limit="25" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis for the test was no difference between groups.</non_inferiority_desc>
            <p_value>0.006</p_value>
            <p_value_desc>The significance level for this test was 0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>We used an exact Wilcoxon rank sum test due to the skewed nature of the morphine equivalents data and the small sample sizes in each group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Hospital Stay</title>
        <description>Primary outcomes include length of hospital stay (LOS).</description>
        <time_frame>82.25 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Primary outcomes include length of hospital stay (LOS).</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="46.5" upper_limit="56"/>
                    <measurement group_id="O2" value="57.3" lower_limit="50.6" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis was no difference between groups.</non_inferiority_desc>
            <p_value>0.029</p_value>
            <method>Exact Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine Levels at One Year Post-operatively</title>
        <description>Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Levels at One Year Post-operatively</title>
          <description>Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.6" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.6" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety outcome was used to power our study.To achieve 90% power at a 2.5% significance level for testing that the post-surgery creatinine increase is at most two-fold (where 1.5 fold is expected), or alternatively for the pre-surgery creatinine group to be â‰¥0.5 times the post-surgery, we need 17 subjects in the toradol group. This calculation was based on a non-inferiority test (one sided t-test) using a coefficient of variation of 0.25 based on preliminary data.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>We conducted a 1-sided non-inferiority test using an alpha level of 0.025, for a comparison of the fold change of creatinine levels (pre-operative creatinine/post-operative creatinine) in the Toradol group. Our minimum non-inferiority margin was 0.5, ie the post-operative creatinine level could only increase to at most two times the pre-operative creatinine level.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This p-value was compared to a significance threshold of 0.025.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Risk</title>
        <description>Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Risk</title>
          <description>Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.</description>
          <units>percentage of hematocrit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.1"/>
                    <measurement group_id="O2" value="4.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis was no difference between groups.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Urinary Retention</title>
        <description>Patients were evaluated post-operatively during hospital stay for instances of urinary retention.</description>
        <time_frame>82.25 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Urinary Retention</title>
          <description>Patients were evaluated post-operatively during hospital stay for instances of urinary retention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis was no difference between groups.</non_inferiority_desc>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day Mortality</title>
        <description>Primary outcomes include 30 day mortality post-operatively.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Toradol and Lyrica</title>
            <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Standard of Care</title>
            <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day Mortality</title>
          <description>Primary outcomes include 30 day mortality post-operatively.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Toradol and Lyrica</title>
          <description>Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
Ketorolac: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Pregabalin: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Standard of Care</title>
          <description>Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
Placebo oral capsule: Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eryberto Martinez</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-2563</phone>
      <email>eddie.martinez@utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

